Vericel is a biopharmaceutical company that develops and commercializes advanced cell therapies and specialty biologics for orthopedic and burn care markets. Its core products include MACI, an autologous cell therapy for repairing knee cartilage defects that uses a patient's own cells; Epicel, a cultured skin replacement for severe burn patients; and NexoBrid, a topical enzyme treatment for burn wound management. The company generates revenue by manufacturing personalized implants and biologics, which it distributes through specialty pharmacies and directly to hospitals and burn centers, with reimbursement typically obtained through commercial insurance coverage or case-by-case authorization. Vericel serves orthopedic surgeons and specialized burn centers across the United States, targeting a combined addressable market of hundreds of thousands of eligible patients annually.